Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RET-fusion Non Small Cell Lung Cancer”

28 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 28 results

Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Who this might be right for
Solid TumorMedullary Thyroid Cancer
Eli Lilly and Company 77
Testing effectiveness (Phase 2)Looking for participantsNCT01639508
What this trial is testing

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 86
Large-scale testing (Phase 3)Ended earlyNCT04222972
What this trial is testing

Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Hoffmann-La Roche 223
Large-scale testing (Phase 3)Active Not RecruitingNCT04194944
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 261
Testing effectiveness (Phase 2)Ended earlyNCT04161391
What this trial is testing

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more
Turning Point Therapeutics, Inc. 41
Not applicableNot Yet RecruitingNCT07418879
What this trial is testing

A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

Who this might be right for
Non-small Cell Lung CancerRET FusionPralsetinib
Fudan University 25
Not applicableUnknownNCT04322591
What this trial is testing

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 70
Large-scale testing (Phase 3)Looking for participantsNCT06031558
What this trial is testing

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD 120
Not applicableNo Longer AvailableNCT05225259
What this trial is testing

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Who this might be right for
Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Eli Lilly and Company
Not applicableLooking for participantsNCT04900935
What this trial is testing

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Who this might be right for
Stage IV Non-small Cell Lung CancerTargeted TherapyNonsmall Cell Lung Cancer+5 more
Massachusetts General Hospital 70
Testing effectiveness (Phase 2)Study completedNCT01823068
What this trial is testing

Vandetanib in Advanced NSCLC With RET Rearrangement

Who this might be right for
Non Small Cell Lung Cancer
Samsung Medical Center 17
Testing effectiveness (Phase 2)UnknownNCT05117658
What this trial is testing

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 83
Testing effectiveness (Phase 2)UnknownNCT05675605
What this trial is testing

TY-1091 in Patients With Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+1 more
TYK Medicines, Inc 248
Testing effectiveness (Phase 2)UnknownNCT02540824
What this trial is testing

Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Tongji University 40
Testing effectiveness (Phase 2)WithdrawnNCT05364645
What this trial is testing

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Who this might be right for
Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+2 more
SWOG Cancer Research Network
Testing effectiveness (Phase 2)Active Not RecruitingNCT05845671
What this trial is testing

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Who this might be right for
Lung CancerNon Small Cell Lung Cancer
University of Colorado, Denver 12
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04268550
What this trial is testing

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
SWOG Cancer Research Network 124
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128
What this trial is testing

Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more
Eli Lilly and Company 857
Load More Results